Why Zealand and Roche’s weight loss drug flopped
Zealand Pharma’s shares plummet following the phase 2 study results of the obesity drug petrelintide developed with Roche, as efficacy data fall short of investor expectations compared to rival treatments from Eli Lilly and Novo Nordisk. Facts, figures, and comments.
